Taro Pharmaceutical Financials
| TARO Stock | USD 42.25 0.06 0.14% |
| Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Operating Income | 19.4 M | 20.4 M |
|
| |||||
| Current Ratio | 2.5 | 3.054 |
|
|
The financial analysis of Taro Pharmaceutical is a critical element in measuring its lifeblood. The essential information of the day-to-day investment outlook for Taro Pharmaceutical includes many different criteria found on its balance sheet. For example, investors should never minimize Taro Pharmaceutical's ability to pay suppliers or employees on time, making sure interest payments are not accumulating or correctly timing where and how to re-invest extra cash. Any individual investor needs to monitor Taro Pharmaceutical's cash flow, debt, and profitability to effectively and accurately make more informed decisions on whether to invest in Taro Pharmaceutical.
Net Income |
|
With this module, you can analyze Taro financials for your investing period. You should be able to track the changes in Taro Pharmaceutical individual financial statements over time to develop the understanding of its risk, liquidity, profitability, or other critical and vital indicators.
Taro | Select Account or Indicator |
Understanding current and past Taro Pharmaceutical Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of Taro Pharmaceutical's financial statements are interrelated, with each one affecting the others. For example, an increase in Taro Pharmaceutical's assets may result in an increase in income on the income statement.
The data published in Taro Pharmaceutical's official financial statements usually reflect Taro Pharmaceutical's business processes, product offerings, services, and other fundamental events. But there are other numbers, ratios, or fundamental indicators derived from these statements that are easier to understand and visualize within the underlying realities that drive quantitative information of Taro Pharmaceutical. For example, before you start analyzing numbers published by Taro accountants, it's critical to develop an understanding of what Taro Pharmaceutical's liquidity, profitability, and earnings quality are in the context of the Pharmaceuticals space in which it operates.
Please note, the presentation of Taro Pharmaceutical's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Taro Pharmaceutical's management is honest, while the outside auditors are strict and uncompromising. Whatever the case, the imprecision that can be found in Taro Pharmaceutical's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Taro Pharmaceutical Industries. Please utilize our Beneish M Score to check the likelihood of Taro Pharmaceutical's management manipulating its earnings.
Taro Pharmaceutical Stock Summary
Taro Pharmaceutical competes with Alkermes Plc, Ironwood Pharmaceuticals, Deciphera Pharmaceuticals, Eagle Pharmaceuticals, and Neurocrine Biosciences. Taro Pharmaceutical Industries Ltd., a science-based pharmaceutical company, develops, manufactures, and markets prescription and over-the-counter pharmaceutical products in the United States, Canada, Israel, and internationally. Taro Pharmaceutical Industries Ltd. is a subsidiary of Alkaloida Chemical Company Exclusive Group Ltd. Taro Pharm operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on New York Stock Exchange. It employs 1455 people.Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Instrument | USA Stock View All |
| Exchange | New York Stock Exchange |
| ISIN | IL0010827181 |
| CUSIP | M8737E108 |
| Location | Israel |
| Business Address | 14 Hakitor Street, |
| Sector | Pharmaceuticals |
| Industry | Health Care |
| Benchmark | NYSE Composite |
| Website | www.taro.com |
| Phone | 972 4 847 5700 |
| Currency | USD - US Dollar |
You should never invest in Taro Pharmaceutical without having analyzed its financial statements. Do not rely on someone else's analysis or guesses about the future performance of Taro Stock, because this is throwing your money away. Analyzing the key information contained in Taro Pharmaceutical's financial statements can give you an edge over other investors and help to ensure that your investments perform well for you.
Taro Pharmaceutical Key Financial Ratios
Generally speaking, Taro Pharmaceutical's financial ratios allow both analysts and investors to convert raw data from Taro Pharmaceutical's financial statements into concise, actionable information that can be used to evaluate the performance of Taro Pharmaceutical over time and compare it to other companies across industries. There are many critical financial ratios that investors are exposed to on a daily basis, but they are usually grouped into few meaningful categories from each financial statement that Taro Pharmaceutical reports annually and quarterly.| Return On Equity | 0.0261 | ||||
| Profit Margin | 0.07 % | ||||
| Operating Margin | 0.11 % |
Taro Pharmaceutical Key Balance Sheet Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Total Assets | 2.3B | 2.4B | 2.2B | 2.1B | 2.5B | 2.6B | |
| Other Current Liab | 192.1M | 605.9M | 355.9M | 314.2M | 361.3M | 379.4M | |
| Net Debt | (511.8M) | (603.5M) | (248.9M) | (152.5M) | (137.3M) | (144.2M) | |
| Retained Earnings | 2.7B | 2.3B | 2.4B | 2.4B | 2.8B | 2.9B | |
| Cash | 513.4M | 605.2M | 251.1M | 154.5M | 177.7M | 180.1M | |
| Net Receivables | 270.8M | 266.9M | 306.7M | 259.5M | 298.4M | 149.6M | |
| Inventory | 153.1M | 180.3M | 210.4M | 226.7M | 260.7M | 273.7M | |
| Total Liab | 231.5M | 711.4M | 464.9M | 404.7M | 465.4M | 488.6M | |
| Total Current Assets | 1.5B | 1.5B | 1.3B | 1.3B | 1.5B | 1.6B | |
| Short Term Debt | 1.5M | 1.7M | 2.2M | 2.0M | 2.2M | 2.1M | |
| Intangible Assets | 21.7M | 19.8M | 60.1M | 76.1M | 87.6M | 91.9M | |
| Accounts Payable | 28.9M | 61.2M | 68.2M | 68.5M | 78.8M | 74.3M | |
| Other Current Assets | 8.8M | 12.9M | 14.2M | (1K) | (1.2K) | (1.1K) | |
| Other Liab | 7.4M | 7.6M | 33.8M | 28.8M | 33.2M | 34.8M | |
| Other Assets | 126.0M | 121.3M | 156.6M | 139.0M | 159.9M | 167.9M | |
| Net Tangible Assets | 1.9B | 2.1B | 1.7B | 1.6B | 1.9B | 1.9B | |
| Net Invested Capital | 2.1B | 1.7B | 1.7B | 1.7B | 1.6B | 1.5B |
Taro Pharmaceutical Key Income Statement Accounts
An income statement is very similar to a cash flow statement, but instead of showing net revenue minus expenses, it only includes earnings before interest and taxes (EBIT). This number does not have all of the same line items that are on a cash flow statement, but it leaves out non-cash expenses like depreciation and amortization. For example, if you bought $100 worth of goods from Walmart (WMT) using your debit card that has an interest rate of 20%, then paid off the balance at the end of the month with a credit card that charges 30% interest, you would have an income statement showing EBIT of $80 because your expenses are lower than the amount that went into your pocket. The other reason investors look at the income statement is to determine what Taro Pharmaceutical's earnings per share (EPS) will be in order to see if they want to buy more shares or not. For example, if a company earned $20 million in the last quarter and has 100,000 shares outstanding, its EPS is 20 cents. If you find that this number beats analysts' forecasts or is higher than it was from the same period last year, then you might want to buy more of this stock even though its price per share may not have changed.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Total Revenue | 644.8M | 549.0M | 561.3M | 573.0M | 658.9M | 356.7M | |
| Gross Profit | 399.7M | 296.7M | 293.1M | 268.3M | 308.6M | 235.8M | |
| Operating Income | 246.5M | 704.4M | 184.4M | 17.7M | 20.4M | 19.4M | |
| Ebit | 246.5M | 704.4M | 184.4M | 17.7M | 20.4M | 19.4M | |
| Ebitda | 253.1M | 728.1M | 210.3M | 52.7M | 60.6M | 57.5M | |
| Cost Of Revenue | 245.0M | 252.3M | 268.2M | 304.6M | 350.3M | 367.8M | |
| Income Before Tax | 298.0M | (391.1M) | 77.9M | 38.2M | 43.9M | 41.7M | |
| Income Tax Expense | 53.5M | 9.7M | 19.6M | 12.8M | 14.7M | 24.0M | |
| Net Income | 244.2M | (400.7M) | 58.3M | 25.4M | 29.3M | 27.8M | |
| Research Development | 59.8M | 60.2M | 54.5M | 52.2M | 60.1M | 45.0M | |
| Interest Expense | 725K | 1.4M | 1.7M | (17.7M) | (15.9M) | (15.1M) | |
| Minority Interest | 5.2M | 5.6M | 5.9M | (8.2M) | (904K) | 0.0 | |
| Tax Provision | 53.5M | 9.7M | 19.6M | 12.8M | 11.5M | 10.9M | |
| Interest Income | 22.7M | 20.2M | 8.2M | 20.9M | 18.8M | 14.6M | |
| Net Interest Income | 33.6M | 20.2M | 8.2M | 20.9M | 18.8M | 17.2M |
Taro Pharmaceutical Key Cash Accounts
Cash flow analysis captures how much money flows into and out of Taro Pharmaceutical. It measures of how well Taro is doing because it can show the actual money that comes into and out of the Company from sales instead of measuring expenses against revenue to determine earnings. You have to read the cash flow statement in three sections. The first section shows how much money Taro Pharmaceutical brought in, usually known as net revenue or sales. This is different from earnings because it does not include expenses when determining net revenue for use on this part of the cash flow statement. Next, are operating activities, which show how much money Taro had leftover after paying for its expenses. This number can be calculated in two ways: by subtracting the total of all operating expenses from net revenue or by adding up changes to cash and other assets or liabilities on this part of the statement. The third section is about investing activities, which shows what Taro Pharmaceutical has done with the money that it received from the sale of assets or what it spent to acquire new ones. This section can be broken down into two parts: investing in existing businesses (in other words, buying more stock) and investing in non-business activities like paying off debt or making acquisitions.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Change To Inventory | (5.0M) | (27.2M) | (2.1M) | (16.9M) | (15.2M) | (14.5M) | |
| Change In Cash | (54.1M) | 91.8M | (354.0M) | (96.6M) | (87.0M) | (82.6M) | |
| Free Cash Flow | 243.2M | 28.6M | (170.7M) | 13.9M | 16.0M | 15.2M | |
| Depreciation | 21.4M | 23.7M | 25.9M | 32.1M | 36.9M | 38.8M | |
| Other Non Cash Items | (12.6M) | 584K | 13.0M | (4.7M) | (4.2M) | (4.0M) | |
| Capital Expenditures | 28.4M | 17.1M | 12.0M | 17.8M | 20.5M | 21.4M | |
| Net Income | 244.6M | (400.7M) | 58.3M | 25.4M | 29.3M | 27.8M | |
| End Period Cash Flow | 513.4M | 605.2M | 251.1M | 154.5M | 177.7M | 203.6M | |
| Change To Netincome | (17.0M) | (2.0M) | (51.7M) | 36.1M | 41.6M | 43.6M | |
| Investments | (298.2M) | 84.9M | (66.7M) | (125.6M) | (144.4M) | (151.6M) |
Taro Financial Ratios Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Taro Pharmaceutical's current stock value. Our valuation model uses many indicators to compare Taro Pharmaceutical value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Taro Pharmaceutical competition to find correlations between indicators driving Taro Pharmaceutical's intrinsic value. More Info.Taro Pharmaceutical Industries is rated fourth in return on equity category among related companies. It is rated fifth in return on asset category among related companies reporting about 0.39 of Return On Asset per Return On Equity. The ratio of Return On Equity to Return On Asset for Taro Pharmaceutical Industries is roughly 2.53 . At this time, Taro Pharmaceutical's Return On Equity is very stable compared to the past year.Comparative valuation analysis is a catch-all model that can be used if you cannot value Taro Pharmaceutical by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Taro Pharmaceutical's Stock. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Taro Pharmaceutical's earnings, one of the primary drivers of an investment's value.Taro Pharmaceutical Systematic Risk
Taro Pharmaceutical's systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Taro Pharmaceutical volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
Incorrect Input. Please change your parameters or increase the time horizon required for running this function. The output start index for this execution was zero with a total number of output elements of zero. The Beta measures systematic risk based on how returns on Taro Pharmaceutical correlated with the market. If Beta is less than 0 Taro Pharmaceutical generally moves in the opposite direction as compared to the market. If Taro Pharmaceutical Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Taro Pharmaceutical is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Taro Pharmaceutical is generally in the same direction as the market. If Beta > 1 Taro Pharmaceutical moves generally in the same direction as, but more than the movement of the benchmark.
About Taro Pharmaceutical Financials
What exactly are Taro Pharmaceutical Financials? Typically, a company's financial statements are the reports that show the financial position of the company. Three primary documents fall into the category of financial statements. These documents include Taro Pharmaceutical's income statement, its balance sheet, and the statement of cash flows. Potential Taro Pharmaceutical investors and stakeholders use financial statements to determine how well the company is positioned to perform in the future. Although Taro Pharmaceutical investors may use each financial statement separately, they are all related. The changes in Taro Pharmaceutical's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Taro Pharmaceutical's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. Please read more on our technical analysis and fundamental analysis pages.Steps to analyze Taro Pharmaceutical Financials for Investing
There are several different ways that investors can use financial statements to try and predict whether a stock price will go up or down. Unfortunately, there is no surefire formula, but there are some general guidelines you should consider when looking at the numbers. First, realize what kind of company it is so you know if its revenues are more likely to grow or shrink over time. For example, a software company's revenue is expected to increase yearly due to new products and services that its customers will want to buy. At the same time, a car manufacturer might not be able to sell as many cars when the economy slows down, so it would have less net income during those times. Second, pay attention to its debt-to-equity ratio because this number will tell you how much risk it has. If a company such as Taro Pharmaceutical is not taking on any additional risks, its debt-to-equity should be less than one. As a general rule of thumb, if the market value or book value (which can be found in the footnotes) of assets exceeds the company's liabilities, then it is probably in good shape. Finally, use other financial statements to determine if a stock price will go up or down because investors are always looking for growth opportunities when they buy new stocks. For example, if you see that the net revenue of Taro has grown by more than 25% over the last five years, then there is a good chance that it will continue growing by at least 20% or more each year. On the other hand, if you see that net revenue has only increased by about 15%, which is barely above inflation levels, then chances are it will not grow much faster than this over time, and investors may shy away from buying it. In summary, you can determine if Taro Pharmaceutical's financials are consistent with your investment objective using the following steps:- Review Taro Pharmaceutical's balance sheet accounts, such as liabilities and equity, to understand its overall financial position.
- Analyze the income statement and examine the company's revenue, expenses, and profits over time to determine its financial performance.
- Study the cash flow inflows and outflows to understand Taro Pharmaceutical's liquidity and solvency.
- Look at the growth rates in revenue, earnings, and cash flow over time to determine its potential for future growth.
- Compare Taro Pharmaceutical's financials to those of its peers to see how it stacks up and identify any potential red flags.
- Use valuation ratios to evaluate the company's financials using commonly used ratios such as the price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and enterprise value-to-earnings before interest, taxes, depreciation, and amortization (EV/EBITDA) ratio to determine if Taro Pharmaceutical's stock is overvalued or undervalued.
Taro Pharmaceutical Thematic Clasifications
Taro Pharmaceutical Industries is part of several thematic ideas from Obamacare to Israel Wall Street. If you are a theme-oriented, socially responsible, and at the same time, a result-driven investor, you can align your investing habits with your values without jeopardizing your expectations about returns. You can easily create an optimal portfolio of stocks, ETFs, funds, or cryptocurrencies based on a specific theme of your liking. Get More Thematic IdeasToday, most investors in Taro Pharmaceutical Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Taro Pharmaceutical's growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of Taro Pharmaceutical growth as a starting point in their analysis.
Price Earnings To Growth Ratio |
|
Taro Pharmaceutical April 19, 2024 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of Taro Pharmaceutical help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Taro Pharmaceutical Industries. We use our internally-developed statistical techniques to arrive at the intrinsic value of Taro Pharmaceutical Industries based on widely used predictive technical indicators. In general, we focus on analyzing Taro Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Taro Pharmaceutical's daily price indicators and compare them against related drivers.
| Downside Deviation | 0.5476 | |||
| Information Ratio | (0.03) | |||
| Maximum Drawdown | 5.18 | |||
| Value At Risk | (0.47) | |||
| Potential Upside | 1.22 |
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Taro Pharmaceutical Industries. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in metropolitan statistical area. You can also try the Portfolio File Import module to quickly import all of your third-party portfolios from your local drive in csv format.
Complementary Tools for Taro Stock analysis
When running Taro Pharmaceutical's price analysis, check to measure Taro Pharmaceutical's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Taro Pharmaceutical is operating at the current time. Most of Taro Pharmaceutical's value examination focuses on studying past and present price action to predict the probability of Taro Pharmaceutical's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Taro Pharmaceutical's price. Additionally, you may evaluate how the addition of Taro Pharmaceutical to your portfolios can decrease your overall portfolio volatility.
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
| Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
| ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
| Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. | |
| Global Correlations Find global opportunities by holding instruments from different markets | |
| Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
| Bonds Directory Find actively traded corporate debentures issued by US companies | |
| Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals |
Is Taro Pharmaceutical's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Taro Pharmaceutical. If investors know Taro will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Taro Pharmaceutical listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 1.782 | Earnings Share 1.22 | Revenue Per Share 16.252 | Quarterly Revenue Growth 0.129 | Return On Assets 0.0103 |
The market value of Taro Pharmaceutical is measured differently than its book value, which is the value of Taro that is recorded on the company's balance sheet. Investors also form their own opinion of Taro Pharmaceutical's value that differs from its market value or its book value, called intrinsic value, which is Taro Pharmaceutical's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Taro Pharmaceutical's market value can be influenced by many factors that don't directly affect Taro Pharmaceutical's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Taro Pharmaceutical's value and its price as these two are different measures arrived at by different means. Investors typically determine if Taro Pharmaceutical is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Taro Pharmaceutical's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.